Olaparib — Drug Intelligence | 70 EU Trials

Filter these 70 trials by condition, phase, country and more.

Open in Search →

70 Registered trials

30 Recruiting

35 Completed trials

43 Sponsors

25 Countries

Phase III

Phase II

Phase III: 21 Phase II/III: 1 Phase II: 38 Phase I/II: 3 Phase III/IV: 1 Phase IV: 3 Phase I (Other): 1 Phase I (FiH): 2

Oversight events:

3 serious breaches 15 temporary halts 2 urgent safety measures 1 unexpected event across 7 trials

View oversight register →

Indications tested

Ovarian cancer 7 Triple negative breast cancer 5 Fallopian tube cancer 4 Ovarian cancer recurrent 4 Breast cancer 3 Breast cancer metastatic 3 Ovarian epithelial cancer 2 Endometrial cancer 2 Breast cancer female 2 Fallopian tube cancer metastatic 1 Non-small cell lung cancer 1 Prostate cancer metastatic 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 12 AstraZeneca AB 11 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 3 IRCCS Istituto Nazionale Tumori Fondazione Pascale 3 AGO Research GmbH 2 Institut Gustave Roussy 2 Region Hovedstaden 2 Artios Pharma Limited 1 Asociacion Grupo Tratamiento De Tumores Digestivos 1 Astrazeneca Farmaceutica Spain S.A. 1 Azienda Ospedaliero Universitaria Di Modena 1 Belgian Society Of Medical Oncology 1

All trials

70 total

The assessment of bevacizumab dose equivalence in ovarian cancer Pending

2023-509659-15-00 Phase IV 1 country Uniwersytet Medyczny W Lublinie
[18F]-olaparib PET; Molecular imaging of DNA damage response by [18F]-olaparib PET Pending

2024-511962-34-00 Phase I (FiH) 1 country Universitair Medisch Centrum Groningen
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent O… Pending

2024-516327-14-00 Phase II 9 countries Nordic Society Of Gynaecological Oncology Clinical Trial Unit
Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending

2025-522431-34-00 Phase II 1 country Region Hovedstaden
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Phase III 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
PASSION (olaParib mAintenance in chemotherapy-Sensitive metaStatic pancreatIc adenOcarciNoma - mPDAC): a phase II, proof of principle, study Recruiting

2025-522530-31-01 Phase II 1 country Universita' Degli Studi Di Verona
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients Recruiting

2023-509220-17-00 Phase I (FiH) 1 country Artios Pharma Limited
A clinical study of patritumab deruxtecan in people with breast cancer Recruiting

2024-514376-40-00 Phase II 1 country Merck Sharp & Dohme LLC
SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial Recruiting

2024-512132-29-00 Phase II 1 country Swiss Group for Clinical Cancer Research
zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting

2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
Study of MK-5684-based Therapies in Advanced Prostate Cancer Recruiting

2023-506288-33-00 Phase I/II 8 countries Merck Sharp & Dohme LLC
MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The M… Recruiting

2024-516841-38-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th… Recruiting

2024-516842-21-00 Phase III 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in … Recruiting

2023-504925-38-00 Phase II 1 country GBG Forschungs GmbH
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting

2024-516839-27-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
A Phase II Multicentric Study of Olaparib in PALB2-related Advanced Pancreatic Cancer (PALBOLA) Recruiting

2024-516466-11-00 Phase II 1 country Azienda Ospedaliero Universitaria Di Modena
FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting

2024-517478-68-01 Phase II 1 country HUS-Yhtymae
Maintenance of durvalumab and olaparib after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive ext… Recruiting

2024-512373-27-00 Phase II 1 country University Of Cologne
Study in children and adolescents for the treatment of recurrent or relapsed solid tumours with the treatment of Lutathera® combined with ol… Recruiting

2024-512613-40-00 Phase I/II 1 country Fundacion De investigacion De Hm Hospitales
Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials – p53abn - RED Randomized phase … Recruiting

2023-503886-44-00 Phase III 1 country Institut Gustave Roussy
Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced … Recruiting

2024-517363-24-00 Phase II 1 country Vall D Hebron Institute Of Oncology
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv… Recruiting

2022-502254-13-00 Phase III 1 country UZ Leuven
Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study … Recruiting

2024-514022-23-00 Phase II 1 country Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Phase 2 trial of Translational approach to first line cHemoimmunotherapy followed by maintenance with pembrOlizumab and olaparib in Extensiv… Recruiting

2024-514666-39-00 Phase II 1 country Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Showing 1–24 of 70 trials

← All drugs A–Z